Biontech SE BNTX.OQ, BNTX.O is expected to show a fall in quarterly revenue when it reports results on November 3 for the period ending September 30 2025
The Mainz Rheinland-pfalz-based company is expected to report a 22.9% decrease in revenue to €960.343 million from €1.24 billion a year ago, according to the mean estimate from 11 analysts, based on LSEG data.
LSEG's mean analyst estimate for Biontech SE is for a loss of 17 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Biontech SE is $136.50, about 23.3% above its last closing price of $104.67
Previous quarterly performance (using preferred earnings measure in euros).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -2.43 | -2.47 | -1.60 | Beat | 35.2 |
Mar. 31 2025 | -2.14 | -2.09 | -1.73 | Beat | 17.2 |
Dec. 31 2024 | 0.62 | 0.33 | 1.08 | Beat | 231.9 |
Sep. 30 2024 | -1.26 | -1.56 | 0.81 | Beat | 151.9 |
Jun. 30 2024 | -2.10 | -2.02 | -3.36 | Missed | -66.1 |
Mar. 31 2024 | -1.26 | -1.09 | -1.31 | Missed | -20.6 |
Dec. 31 2023 | 2.25 | 2.42 | 1.90 | Missed | -21.5 |
Sep. 30 2023 | -0.91 | -0.10 | 0.67 | Beat | 796.1 |
This summary was machine generated October 31 at 14:51 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)